Ghirardi V, Ronsini C, Trozzi R, et al. - A recent report by a randomized controlled trial has shown that hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) afforded an improvement in survival without increasing perioperative morbidity in patients suffering from advanced epithelial ovarian cancer, and therefore, researchers investigated the feasibility as well as perioperative results of the use of HIPEC following IDS at a referral cancer center. A total of 149 IDSs were performed during the study span. HIPEC was administered in patients with at least International Federation of Gynecology and Obstetrics stage III disease, with < 2.5 mm of residual disease at the end of surgery and were not engaging in clinical trials. As per findings, HIPEC when added to IDS was found to be feasible in 35% for the population. In association with alterations in the inclusion/exclusion criteria, this value might increase. No increase in perioperative complications as well as no impact on a patient's recovery or time to initiate adjuvant chemotherapy was conferred by HIPEC. Based on these data, HIPEC was recommended to be offered to select patients listed for IDS.